These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1403066)

  • 21. Penetration of ciprofloxacin and its desethylenemetabolite into skin in humans after a single oral dose of the parent drug assessed by cutaneous microdialysis.
    Bielecka-Grzela S; Klimowicz A
    J Clin Pharm Ther; 2005 Aug; 30(4):383-90. PubMed ID: 15985052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin.
    Rohwedder R; Bergan T; Caruso E; Thorsteinsson SB; Della Torre H; Scholl H
    Chemotherapy; 1991; 37(4):229-38. PubMed ID: 1790720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain tissue penetration of ciprofloxacin following a single intravenous dose.
    Leone M; Sampol-Manos E; Santelli D; Grabowski S; Alliez B; Durand A; Lacarelle B; Martin C
    J Antimicrob Chemother; 2002 Oct; 50(4):607-9. PubMed ID: 12356810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corneal stromal penetration of topical ciprofloxacin in humans.
    McDermott ML; Tran TD; Cowden JW; Buggé CJ
    Ophthalmology; 1993 Feb; 100(2):197-200. PubMed ID: 8437827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetration of ciprofloxacin into gynecologic tissues.
    Dalhoff A; Weuta H
    Am J Med; 1987 Apr; 82(4A):133-8. PubMed ID: 3555027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes.
    Beck R; van Keyserlingk J; Fischer U; Guthoff R; Drewelow B
    Graefes Arch Clin Exp Ophthalmol; 1999 Feb; 237(2):89-92. PubMed ID: 9987622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung tissue concentrations of ciprofloxacin following intravenous administration in patients.
    Forst H; Ruckdeschel G; Unertl K; Dieterich HJ; Ehret W; Sunder-Plassmann L
    Arzneimittelforschung; 1989 May; 39(5):618-9. PubMed ID: 2757681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral treatment of CAPD-peritonitis with ciprofloxacin.
    Boeschoten EW; Kuijper EJ; Speelman P; Struijk DG; Krediet RT; Arisz L
    Adv Perit Dial; 1990; 6():126-9. PubMed ID: 1982789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
    Frost RW; Lettieri JT; Krol G; Shamblen EC; Lasseter KC
    Clin Pharmacol Ther; 1989 Jun; 45(6):608-16. PubMed ID: 2731404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tear concentrations of topically applied ciprofloxacin.
    Limberg M; Buggé C
    Cornea; 1994 Nov; 13(6):496-9. PubMed ID: 7842707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of ciprofloxacin after single oral doses in patients with septicemia.
    D'Espine M; Bellido F; Pechère JC; Auckenthaler R; Rohner P; Lew D; Hirschel B
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1019-23. PubMed ID: 2620671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
    Varela JE; Cohn SM; Brown M; Ward CG; Namias N; Spalding PB
    J Antimicrob Chemother; 2000 Mar; 45(3):337-42. PubMed ID: 10702553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Fass RJ; Plouffe JF; Russell JA
    Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciprofloxacin concentrations in human fluids and tissues following a single oral dose.
    Esposito S; Galante D; Barba D; D'Errico G; Mazzone A; Montanaro S
    Int J Clin Pharmacol Res; 1987; 7(3):181-6. PubMed ID: 3596861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.
    de Marie S; VandenBergh MF; Buijk SL; Bruining HA; van Vliet A; Kluytmans JA; Mouton JW
    Intensive Care Med; 1998 Apr; 24(4):343-6. PubMed ID: 9609412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Penetration of ciprofloxacin in bronchial secretions after intravenous administration.
    Berré J; Thys JP; Husson M; Gangji D; Klastersky J
    J Antimicrob Chemother; 1988 Oct; 22(4):499-504. PubMed ID: 3204076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of trough concentrations of oral ciprofloxacin.
    Paladino JA; Forrest A; Wilton JH
    Pharmacotherapy; 1993; 13(5):504-7. PubMed ID: 8247920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue penetration and metabolism of ciprofloxacin.
    Wise R; Donovan IA
    Am J Med; 1987 Apr; 82(4A):103-7. PubMed ID: 3578319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.